Skip to main content

Advertisement

Table 6 Cytotoxicity of compounds 15, 16, 17, 18, 19, 20 and Doxorubicin against breast carcinoma cell line MCF-7

From: Design, synthesis and evaluation of anticancer activity of novel 2-thioxoimidazolidin-4-one derivatives bearing pyrazole, triazole and benzoxazole moieties

Concentration µg/mL Viability (%)/compound
15 16 17 18 19 20 Doxorubicin
500 8.76 5.28 7.95 6.17 5.21 8.25 1.51
250 13.81 13.96 21.34 13.92 11.36 16.37 2.36
125 26.92 21.47 30.67 21.40 20.84 28.72 3.21
62.5 37.24 32.68 38.72 28.57 27.30 41.89 5.07
31.25 48.17 36.43 51.90 36.71 35.26 49.78 6.93
15.6 60.95 42.90 64.18 48.86 39.48 80.93 15.46
7.8 76.43 51.72 72.37 69.52 46.29 92.34 19.89
3.9 89.71 69.37 88.45 81.94 54.68 97.28 24.98
2 97.02 83.19 92.32 90.68 69.31 100 31.69
1 100 92.48 97.45 96.25 80.47 100 40.17
0 100 100 100 100 100 100 100